Abstract: Personal care devices (or apparatuses) are described to deliver/activate a bioactive compound/botanical compound/biologically active molecule (including a regulatory protein/growth factor) or a mixture of bioactive compounds/botanical compounds/biologically active molecules (including regulatory proteins/growth factors) for growth and protection of hair or rejuvenation and protection of skin, which utilizes nanoencapsulation/nanoemulsion and/or activation/photoactivation. Such devices (or apparatuses) utilize a light low intensity module/x-ray and nanooptical elements/three-dimensionally (3-D) printed micro/nanostructures.

Abstract: The invention relates to an oral delivery vehicle tablet, the delivery vehicle tablet being formed by compression of a plurality of particles, wherein the oral delivery vehicle tablet comprises sugar alcohol(s) in an amount of 40 to 99.9% by weight of the delivery vehicle tablet, wherein the oral delivery vehicle tablet comprises non-direct compressible (non-DC) erythritol particles in an amount of 15-50% by weight of the delivery vehicle tablet, wherein the oral delivery vehicle tablet comprises one or more binders other than binders granulated to the sugar alcohol(s) in an amount of 0.1 to 6% by weight of the tablet, wherein the delivery vehicle tablet comprises a plurality of further sugar alcohol particles in an amount of at least 10% by weight of the delivery vehicle tablet and wherein said further sugar alcohols particles have a composition which is different from said non-DC erythritol.

Abstract: A skin smoothing composition that has from about 0.5 to about 10%, by weight, of an interpenetrating polymer that is a co-polymer of polyurethane and a polyacrylic polymer. The composition further contains from about 0.1% to about 5%, by weight, of a thickener made from homopolymers of acrylic acid crosslinked with a cross linker selected from the group consisting of an allyl ether pentaerythritol, allyl ether of sucrose, allyl ether of propylene and mixtures thereof and from about 10 to 98% water.

Abstract: Methods for improving the gastrointestinal tolerability of biguanide compounds and for treating metabolic disorders and/or inducing weight loss in patients in need thereof, particularly in individuals having a contraindication for treatment with biguanide compounds, are provided comprising administering delayed release formulations of such biguanide compounds, including metformin, targeted to the small intestine.

Abstract: The present invention relates to an aqueous cosmetic composition which is in the form of a flexible solid, comprising: from 25% to 70% by weight of one or more anionic surfactants and one or more types of non-hollow solid particles, said composition comprising at least one anionic surfactant chosen from acylisethionates, preferably having an acyl group containing from 6 to 30 carbon atoms. Said composition is of preferential use as a composition for cleaning or washing keratin materials, in particular the hair. The invention also relates to a cosmetic treatment process, in particular for caring for, cleaning and/or conditioning keratin materials, using said composition.

Abstract: The present invention relates to an aqueous cosmetic composition in flexible solid form, comprising: at least 12 wt.-% of one or more anionic surfactants, and one or more polymer conditioning agents, said composition comprising at least one anionic surfactant selected from among acyl isethionates. The composition is preferably suitable for use as a composition for cleaning or washing keratin materials, particularly hair. The invention also relates to a cosmetic treatment method intended in particular for the care, cleaning and/or conditioning of keratin materials using said composition.

Abstract: The invention relates an oral delivery vehicle tablet containing nicotine, the delivery vehicle tablet being formed by compression of a plurality of particles, the oral delivery vehicle tablet comprising nicotine, the oral delivery vehicle tablet comprising sugar alcohol(s) in an amount of 40 to 100% by weight of the delivery vehicle tablet, wherein at least 10% by weight of the delivery vehicle tablet comprises a plurality of particles consisting of erythritol and wherein the delivery vehicle tablet comprises a plurality of further sugar alcohol particles in an amount of at least 10% by weight of the delivery vehicle tablet, wherein said further sugar alcohol particles comprise at least one sugar alcohol and wherein said further sugar alcohols particles have a composition which is different from said particles consisting of erythritol.

Abstract: A multi-layered wound care product includes an upper liquid-absorbing layer, an intermediate occlusive layer; and an active agent-releasing bottom layer. The latter two layers have common pores or perforations that enable the passage of wound exudate through the two layers to reach the liquid-absorbing layer. A use of the multi-layered wound care product for treatment of acute and chronic wounds and a method of producing the multi-layered wound care product are also provided.

Abstract: A design for dynamically adjusting parameters applied to a surgical instrument, such as an ocular surgical instrument, is presented. The method includes detecting surgical events from image data collected by a surgical microscope focused on an ocular surgical procedure, establishing a desired response for each detected surgical event, delivering the desired response to the ocular surgical instrument as a set of software instructions, and altering the surgical procedure based on the desired response received as the set of software instructions.

Abstract: A kit for mucosally administering a metastable supersaturated solution of a pharmaceutical active agent to a human patient includes a first compartment comprising a first composition comprising a pharmaceutical active agent in solution at or below equilibrium solubility, and a second composition comprising an acidic buffer. The first and second compartments maintain separation of the first and second compositions during storage, and allow for mixing of the first and second compositions to form a supersaturated solution above equilibrium solubility of the pharmaceutical active agent for immediate mucosal administration to a human patient. In one embodiment, the second composition comprises an acidic buffer and the supersaturated solution has an acidic pH. Alternatively, the second composition comprises a basic buffer and the supersaturated solution has a basic pH.

Abstract: A pharmaceutical composition is provided comprising a highly soluble arsenic carbonate and/or bicarbonate compound and which is useful in the treatment of a variety of cancers, including acute promyelocytic leukaemia. The arsenic carbonate and/or bicarbonate salt acts as a solid, and so orally deliverable, improved bioequivalent delivery form of arsenic trioxide IV solutions.

Abstract: The present invention is a surface treated drug-loaded solid (e.g., non-porous) microparticle that aggregates in vivo to form a consolidated larger particle for medical therapy. In one embodiment, the particles are used for ocular therapy. Processes for producing the surface treated microparticle and injectable formulations which include the surface treated microparticle are also provided. When used in the eye, long-term consistent intraocular delivery can be achieved without disrupting vision and minimizing undesirable inflammatory responses.

Abstract: Nanostructures, compositions and methods for treating vesicle-related or exosome-related conditions are provided. In some cases, the nanostructures and/or compositions may be used to treat cancers, neurological disorders, rheumatologic disorders, viral disorders or other diseases or conditions at least in part by regulating vesicle uptake. Methods of analyzing, imaging and modulating vesicles and cellular vesicles processes are also provided.

Abstract: A sheet-like hair care product including (A) a substrate sheet containing cellulosic fibers and having a bending resistance of 10 to 70 mm measured by the 45° cantilever method in accordance with JIS L1096:2010 and (B) a liquid cosmetic composition. The substrate sheet (A) is impregnated with 1 to 50 g of the liquid cosmetic composition (B). The substrate sheet impregnated with the liquid cosmetic composition is preferably packaged in a packaging container having an access opening with an area of 25 to 4000 mm2 and an openable and closable lid sealing the contents.

Abstract: The present invention provides an apparatus and process for making softgel capsules having incorporated therein other solid dosage forms selected from the group consisting of pellets, smaller capsules, smaller tablets, sustained release solid dosage forms, immediate release solid dosage forms, extended release solid dosage forms and zero order release solid dosage forms, said apparatus comprising: (a) two spreader boxes; (b) two casting drums; (c) a pair of rotary dies having means for suction; (d) a liquid fill system; (e) a wedge for heating gelatine ribbons and feeding said fill; and (f) two lateral dispensing devices said lateral dispensing devices including hoppers having said solid dosage forms, channel guides for transporting said solid dosage forms and a grasping claw for dispensing said solid dosage form into the softgel pocket formed in the rotary dies.

Abstract: Microstructure arrays and methods for using and manufacturing the arrays are described.

Abstract: The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.

Abstract: The present invention relates to a pharmaceutical composition for forming a film directly on a wound to accelerate wound healing, a use for the same, a treatment method using the same, and a method for preparing the same. The film-forming composition according to the present invention forms a film directly on the wound to increase the adhesion to the wound. The formed thin hydrophilic film protects the wound surface to prevent infection of the wound surface, retains the physiologically active substance useful for wound healing on the wound surface to promote the wound healing, and allow drugs to be continuously delivered to the wound surface. Therefore, the composition according to the present invention has excellent wound healing effect and has excellent usability as it is not absorbed into clothing, bandage, etc., thus effectively replacing conventional gel or ointment formations for delivering physiologically active substances.

Abstract: Disclosed are crosslinked particles (e.g., microparticles) that are capable of storing and releasing drugs. The particles can be macroparticles, microparticles, or nanoparticles and can be composed of polyester backbones. The particles can be loaded with a drug. The particles can degrade in vivo to release the drug. The particles can be prepared by crosslinking functionalized polyester backbones and loaded with a given drug. The particles of the present disclosure can be injected with a syringe. In some embodiments, the particles of the present disclosure are administered in connection with a surgery and release the drug after the site of the surgery for a period of 1-6 months.

Abstract: Described are transdermal drug delivery systems for the transdermal administration of levonorgestrel and ethinyl estradiol, comprising an acrylic polymer matrix. Methods of making and using such systems also are described.